Cambridge Heart and Del Mar Reynolds Announce Distribution Agreement.

BEDFORD, Mass. & LONDON -- Cambridge Heart, Inc. (OTCBB:CAMH) and Del Mar Reynolds Medical, Inc., a wholly owned subsidiary of the Ferraris Group PLC (LONDON: FER.L) today announced an agreement that gives distribution rights for Cambridge Heart's CH2000 cardiac stress test system to Del Mar Reynolds Medical Inc. through its US direct sales and distribution channels and selective international markets. The system is expected to be available immediately and is being launched at the American Heart Association meeting in New Orleans. The Companies will work cooperatively to enhance and extend the product platform.

"This strategic alliance allows us to continue the expansion of our product offering and enhances our position as a Cardiac Solutions Provider. This agreement supports our goal of ensuring that our customers, and ultimately their patients, benefit from the latest in medical diagnostic technology," stated Gary Grenter, Group President of Del Mar Reynolds Medical.

"This agreement has great significance to Cambridge Heart as it establishes full U.S. distribution for our CH2000 cardiac stress test system with an experienced and in place sales force while increasing our global reach," stated David Chazanovitz, President and Chief Executive Officer of Cambridge Heart. "The partnership with a leader in the non invasive diagnostic cardiology market allows us to concentrate on our Microvolt T-Wave Alternans business while assuring increased penetration into the stress market place."

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

Cambridge Heart's Safe Harbor Statement

Statements contained in this press release that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the Securities and Exchange Commission.

About Del Mar Reynolds

Del Mar Reynolds, a wholly owned subsidiary of the Ferraris Group, a London based medical diagnostic business, is a global Cardiac Solutions Provider of noninvasive cardiac diagnostic products. Del Mar Reynolds Medical was formed 2003 as a result of the merger of Del Mar Medical Systems and Reynolds Medical. The company has been an innovator in ambulatory monitoring for over 40 years. Additional information is available at www.delmarreynolds.com.

About Ferraris Group

Ferraris is a global medical diagnostic company committed to providing a broad range of products in the cardiac, respiratory, blood and clinical research sectors. Additional information is available at www.ferraris.co.uk.